Oncology Nursing Update: Bispecific Antibodies in Lymphoma Part 1 — An Interview with Ms Robin Klebig
Research To Practice | Oncology Videos · Dr. Neil Love
March 18, 20251h 5m
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Ms Robin Klebig, including the following topics:
- Overview of the natural history and treatment landscapes of lymphoma subtypes (0:00)
- Structure and mechanisms of action of bispecific antibodies (23:41)
- Similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (28:14)
- Case: A man in his early 50s with multiagent/multiregimen-refractory follicular lymphoma who experienced disease progression with chimeric antigen receptor T-cell therapy now receives mosunetuzumab (39:14)
- Case: A woman in her mid 60s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives glofitamab (49:08)
- Case: A man in his mid 60s with R/R high-grade B-cell lymphoma with MYC and Bcl-2 rearrangements receives epcoritamab (52:57)
- Case: A man in his early 60s with composite lymphoma receives epcoritamab (56:55)